Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

4 recruiting

Enrollment Performance

Analytics

Early Phase 1
4(80.0%)
Phase 1
1(20.0%)
5Total
Early Phase 1(4)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT07523100Phase 1Not Yet Recruiting

A Study on the Safety and Tolerability of Universal STAR-T Cell Therapy for Multiple Sclerosis.

Role: lead

NCT07337785Early Phase 1Recruiting

CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases

Role: lead

NCT07303790Early Phase 1Recruiting

This is an Early Exploratory Study to Assess the Tolerability and Safety of GC012F in Patients With Multiple Sclerosis

Role: lead

NCT07086404Early Phase 1Recruiting

GC012F Injection in Refractory Idiopathic Inflammatory Myopathy

Role: lead

NCT07058298Early Phase 1Recruiting

GC012F Injection in the Treatment of Refractory Generalized Myasthenia Gravis(24103)

Role: lead

All 5 trials loaded